Louisiana SB169 clarifies and expands coverage for biomarker testing in health plans.
Louisiana SB169 amends existing law to clarify what constitutes clinical utility for biomarker testing, ensuring coverage is not nullified by unrelated laboratory classifications or credentialing standards. The bill resolves inconsistencies between cancer screening and biomarker testing laws, ensuring coverage applies to the test itself. The law becomes effective upon the governor's signature or, if not signed, upon the expiration of the time for bills to become law without signature.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.